Genetron Health Enters Exclusive Global Licensing Agreement with ImmuQuad Biotechnologies to Develop and Commercialize Minimal Residual Disease Assays in Hematologic Cancer - Seite 2

“ImmuQuad is a pioneer in NGS-based immune profiling with significant first mover advantage in China. Their R&D portfolio in the field of hematologic cancer is highly complementary to Genetron Health’s solid tumor focused diagnostics portfolio,” said Sizhen Wang, co-founder and CEO of Genetron Health. “This licensing agreement accelerates our R&D expertise in the field of MRD testing for hematologic cancers and strengthens our comprehensive diagnostics offering. ImmuQuad’s MRD data is encouraging and we plan to advance the validation in larger cohort studies in multiple hematologic cancer types. We are also excited about ImmuQuad’s promising technology platform, which represents significant market potential. With our equity investment, we plan on working together to advance their immune profiling platform and broadening commercial opportunities in drug discovery in China and other key markets.”

Note:

1. Global Health Data Exchange, http://ghdx.healthdata.org/gbd-results-tool
   

About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

About Hangzhou ImmuQuad Biotechnologies Co., Ltd (ImmuQuad)
Located in Hangzhou, China, ImmuQuad focuses on decoding the adaptive immune system to renovate the diagnosis and treatment of diseases. Its self-developed immune profiling platform can reveal and translate the genetic code of the adaptive immune system and can be applied to the diagnosis, monitoring and treatment of immune-mediated diseases such as cancer, autoimmune diseases, and infectious diseases. ImmuQuad will continue to decode the adaptive immune system and transform its understandings into new products with high-precision and high-efficiency to improve the quality of patients' medical treatment.